{"denoms":[{"counts":[{"groupId":"BG000","value":"14"}],"units":"Participants"}],"groups":[{"description":"erlotinib + celecoxib: In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression","id":"BG000","title":"Erlotinib + Celecoxib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"43","upperLimit":"93","value":"64"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"2"}],"description":"The Eastern Cooperative Oncology Group (ECOG) 0 - Fully active, able to carry on all pre-disease performance without restriction\n\n1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature 2- Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours","paramType":"NUMBER","title":"ECOG Performance Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"None to minimal"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"<20"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"20-40"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":">40"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Unknown"}],"paramType":"NUMBER","title":"Tobacco use, pack-years","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Primary recurrence"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Second or later recurrence"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Second primary cancer"}],"paramType":"NUMBER","title":"Recurrent vs secondary primary","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Squamous cell carcinoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Adenoid cystic"}],"paramType":"NUMBER","title":"Histology","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Sinonasal"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Ear/facial skin"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Oropharynx"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Oral cavity"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Hypopharynx"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Larynx"}],"paramType":"NUMBER","title":"Primary Site","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Tx-T3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"T4"}],"description":"T4 --\\> Tumor of any size with direct extension to chest wall or skin Tx - T3 --\\> any tumor not classified as T4","paramType":"NUMBER","title":"Primary tumor classification","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"N0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}],"title":"N1"}],"description":"N0 - tumor cells absent from regional lymph nodes N1 - regional lymph node metastasis present; (at some sites; tumor spread to closest or small number of regional lymph nodes)","paramType":"NUMBER","title":"Lymph node status","unitOfMeasure":"participants"}],"populationDescription":"15 subjects consented, one withdrew before receiving study treatment and was excluded from analysis"}